|
|
|
28 August 2026
Phil Kerpen, Founder and President of American Commitment, discusses the Inflation Reduction Act’s drug price controls, how they hurt access and innovation, and why they must be repealed and replaced with pro-growth policies and strong intellectual property protections to encourage investment in new life-saving medicines.
0:00
0:00
Related Podcasts
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
28 June 2024
Sally Pipes, President and CEO of Pacific Research Institute, discusses how President Biden's price controls will result in prescription drug shortages and discourage innovation, how government mandates and regulations raise insurance costs, and the grim prognosis on Medicare and Medicaid's viability.
13 October 2022
Sally Pipes, President and CEO of Pacific Research Institute, discusses the likely disastrous effects of drug price control provisions contained in the Inflation Reduction Act and why Congress should embrace a free-market vision when it comes to healthcare by lowering taxes, encouraging innovation and expanding access.
16 September 2022
Phil Kerpen, Founder and President of American Commitment, discusses provisions regarding drug price controls that are contained in the so-called "Inflation Reduction Act" that will negatively impact American's access to necessary drugs and harm innovation, and why the legislation may be unconstitutional.
29 July 2022
Timothy Lee, CFIF's Senior Vice President of Legal and Public Affairs, discusses the potential real world costs of prescription drug price controls, including lost lives, shortages and innovation disincentives, and how drug prices are weathering the inflation storm.
14 February 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at CFIF, discusses the DOJ's civil antitrust lawsuit seeking to block Sabre Corporation's acquisition of Farelogix, Inc., and why imported price controls for drugs is a prescription for failure.
